What's in NORDynamIC Study Group's pipeline?

NORDynamIC Study Group has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with NORDynamIC Study Group's portfolio?

Top competitors by shared drug class: Hepatitis Resource Network, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/nordynamic-study-group.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

NORDynamIC Study Group — Portfolio Competitive Intelligence Brief

NORDynamIC Study Group pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Peginterferon alfa-2a 40KD and Ribavirin	Peginterferon alfa-2a 40KD and Ribavirin	marketed	Interferon alpha with nucleoside analog	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase	Virology / Hepatology

Therapeutic area mix

Virology / Hepatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Hepatitis Resource Network · 1 shared drug class
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for NORDynamIC Study Group:

Cite this brief

Drug Landscape (2026). NORDynamIC Study Group — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nordynamic-study-group. Accessed 2026-05-15.